STOCK TITAN

PERKINELMER INC - PKI STOCK NEWS

Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.

PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.

PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.

In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.

Recent Achievements and Current Projects

  • Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
  • Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
  • Expansion of global reach through new product launches tailored to various market needs.

PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.

Rhea-AI Summary

Revvity (NYSE: RVTY) has secured a favorable ruling from the Massachusetts Superior Court, which will issue a permanent injunction enforcing its agreements with Cloud Software Group (CSG) regarding Spotfire® software. This follows a preliminary injunction from April 2024 and ensures continued access to Spotfire software and support for Revvity and its customers through 2034.

The ruling maintains Revvity's position as the exclusive provider of Spotfire in research and clinical markets, safeguarding operational continuity and service quality for customers. The company expressed satisfaction with the court's decision to uphold the agreements and emphasized its commitment to maintaining service reliability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in four major investor conferences during March 2025. The company's leadership team will present at the following events:

- 46th Annual Raymond James Institutional Investor Conference (March 3, 7:30 a.m. ET) featuring CFO Max Krakowiak
- TD Cowen 45th Annual Health Care Conference (March 4, 9:10 a.m. ET) with CEO Prahlad Singh
- Leerink Partners Global Healthcare Conference (March 11, 8:00 a.m. ET) featuring CEO Prahlad Singh
- KeyBanc Capital Markets Healthcare Forum (March 19, 9:00 a.m. ET) with Steve Willoughby, SVP of Investor Relations

The presentations will provide updates on the company's strategic priorities. Live audio webcasts will be available on the company's website, with replays accessible for at least 30 days following the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Revvity (NYSE: RVTY) reported strong fourth quarter 2024 results with revenue reaching $729 million, representing 5% reported growth and 6% organic growth. The company's Q4 GAAP EPS was $0.78, while adjusted EPS from continuing operations reached $1.42.

For full year 2024, GAAP revenue was $2,755 million compared to $2,751 million in 2023. The Life Sciences segment reported Q4 revenue of $336 million (5% growth), while Diagnostics segment achieved $393 million (4% growth).

Looking ahead, Revvity initiated its 2025 guidance with projected revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on May 9, 2025, to shareholders of record as of the close of business on April 18, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced a strategic agreement with Element Biosciences to develop and commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing. The collaboration combines Revvity's expertise in newborn screening and rare disease detection with Element's AVITI™ sequencing system technology.

The partnership will deliver both an immediate research use only (RUO) version and a comprehensive IVD solution for newborn sequencing. The workflow includes Revvity's sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handlers, NGS library preparation kits with curated NGS panels, and software for variant calling data analysis and interpretation.

This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing workflow for newborn sequencing research and supports Element's progress toward regulatory approval of their benchtop AVITI™ sequencing system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for January 31, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day.

In preliminary Q4 2024 results, Revvity expects reported revenue growth of 5% and organic revenue growth of 6% compared to the previous year, projecting quarterly revenue of approximately $730 million. The company anticipates meeting or exceeding its full year 2024 adjusted earnings per share guidance previously provided on November 4, 2024.

Additionally, CEO Prahlad Singh will present at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025, at 8:15 a.m. PT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Revvity (NYSE: RVTY) has received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This marks a significant milestone as the first FDA-cleared test for direct quantitative measurement of free testosterone levels in human serum or plasma.

The innovative assay, which runs on the company's iSYSTM or i10TM instruments, delivers results in just 48 minutes with a throughput of nearly 60 tests per hour. The test features monoclonal antibodies for consistent performance and specificity across batches.

This advancement enhances diagnostic capabilities for conditions including hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes, offering a user-friendly, random-access platform solution for direct free testosterone measurement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025, at 8:15 a.m. PT in San Francisco. President and CEO Prahlad Singh will present an update on the company's strategic priorities and overall direction. The presentation will be accessible through a live audio webcast, with a replay available on the Revvity Investor Relations website for a minimum of 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. President and CEO Prahlad Singh will present an update on the company and its strategic priorities. The presentation will be accessible through a live audio webcast on the company's website's Events section, with a replay available on the Revvity Investor Relations website for at least 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the market cap of PERKINELMER (PKI)?

The market cap of PERKINELMER (PKI) is approximately 14.5B.

What does PerkinElmer Inc. do?

PerkinElmer provides solutions that help scientists, researchers, and clinicians address challenges in diagnostics, life sciences, food, and applied markets.

What is the mission of PerkinElmer Inc.?

PerkinElmer's mission is to innovate for a healthier world.

How many employees does PerkinElmer Inc. have?

PerkinElmer has approximately 14,000 employees worldwide.

What was PerkinElmer Inc.'s revenue in 2020?

PerkinElmer reported revenues of approximately $3.8 billion in 2020.

In how many countries does PerkinElmer Inc. serve customers?

PerkinElmer serves customers in 190 countries.

What are some of PerkinElmer Inc.'s recent achievements?

Recent achievements include strategic partnerships, investment in innovative technologies, and global expansion through new product launches.

How does PerkinElmer Inc. contribute to healthcare?

PerkinElmer contributes by providing solutions that enable earlier and more accurate healthcare insights.

Is PerkinElmer Inc. part of any major stock index?

Yes, PerkinElmer is a component of the S&P 500 index.

What markets does PerkinElmer Inc. serve?

PerkinElmer serves diagnostics, life sciences, food, and applied markets.

What is a core focus of PerkinElmer Inc.'s partnerships?

PerkinElmer focuses on enabling earlier and more accurate insights through its partnerships.
PERKINELMER INC

NYSE:PKI

PKI Rankings

PKI Stock Data

14.46B
109.03M
0.27%
86.26%
2.79%
Diagnostics & Research
Healthcare
Link
United States
Waltham